Upregulation of syncytin-1 promotes invasion and metastasis by activating epithelial-mesenchymal transition-related pathway in endometrial carcinoma

Changmin Liu, Feifei Wen, Fangfang Yang, Xiaoming Li, Dianzhong Geng, Lei Li, Jiming Chen, Jing Zheng*

1Department of Oncology, Binzhou Medical University Hospital, Binzhou 256603, Shandong, China; 2Department of Obstetrics and Gynecology, Shuyang People’s Hospital, Affiliated to Xuzhou Medical University, Jiangsu, China; 3Department of Pathology, Binzhou Medical University Hospital, Binzhou 256603, Shandong, China; 4Department of Hepatobiliary Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China; 5Department of Obstetrics and Gynecology, The Affiliated Changzhou No 2 People’s Hospital of Nanjing Medical University, Changzhou 213000, Jiangsu, China; 6Department of Clinical Medicine Laboratory, Binzhou Medical University Hospital, Binzhou 256603, Shandong, China

*These authors contributed equally to this work

Background: Endometrial carcinoma (EC) is the most common and lethal malignancy worldwide. Syncytin-1 is expressed in multiple types of cancer. However, the expression pattern and potential mechanism of syncytin-1 and its clinical significance in EC remain unclear.

Materials and methods: We analyzed 130 primary EC specimens from Binzhou Medical University to investigate the clinical role of syncytin-1 in EC by using different advanced pathological stages of EC tissues. Kaplan–Meier analysis was used to measure the overall survival of EC patients. Syncytin-1 expression was analyzed by Western blot assays in HECLCL-1 and RL-95-2 cells. Cell proliferation, cycle, migration, and invasion abilities were detected by cell counting kit-8, flow cytometry, and transwell assays. AKT and epithelial-mesenchymal transition (EMT)-related genes were assessed by Western blot assays in HECLCL-1 and RL-95-2 cells.

Results: Syncytin-1 was upregulated in EC tissues and cells and was related to clinical stages, expression of ER, Ki-67, and overall survival of EC. Functional research revealed that overexpression of syncytin-1 can promote cell proliferation, cell cycle progression, and the migration and invasion of EC cells. Suppression of syncytin-1 expression also inhibited cell proliferation and apoptosis in vitro. The expression of syncytin-1 substantially improved the expression levels of EMT-related genes (vimentin, E-cadherin, slug, and ZEB1) but significantly decreased those of epithelial markers (N-cadherin and snail). In addition, we found that syncytin-1 was not correlated with AKT-related genes (total-AKT, p-AKT, and vinculin).

Conclusion: Our results suggested that syncytin-1 may promote aggressive behavior and can serve as a novel prognostic biomarker for EC. Our study provides new insights into the regulatory mechanism of EMT signaling.

Keywords: syncytin-1, epithelial-mesenchymal transition, endometrial carcinoma

Introduction

Endometrial carcinoma (EC) is one of the most common malignancies and ranks fourth in female cancers. In China, the morbidity and mortality of EC increase with population size, thus prompting an urgent need to develop effective treatments and identify novel therapeutic targets for EC. Multiple factors such as clinical factors (surgical-pathologic staging, depth of myometrial invasion, and adjunctive therapy) and biological factors (steroid receptors, growth factors, oncogenes, and suppressor genes) affect the therapeutic treatment of EC. Immunomodulatory disorders, such as persistent inflammation, play a significant role in its promotion. Anti-inflammatory
molecules may therefore be potential candidates for cancer treatment.

Syncytin-1 belongs to a family of endogenous retroviruses and is the trace left by HERV-W1 after infecting human germ cells.\(^9\)\(^-\)\(^11\) Introduction of syncytin-1 in a cell line prevents retrovirus infection,\(^12\)\(^-\)\(^15\) suggesting that the co-expression of syncytin-1 and its receptor blocks either of the two. In humans, syncytin-1 is most abundantly expressed in the placental trophoblast lineage and may be used as a diagnostic tool in evaluating reproductive potential.\(^16\)\(^-\)\(^19\) In addition, syncytin-1 exhibits antiapoptotic activity in both knockdown and overexpression models in vitro.\(^20\)\(^-\)\(^22\)

The expression of syncytin-1 is activated and upregulated in various malignancies, including breast cancer, ovarian cancer, colorectal cancer, kidney cancer, leukemia, lymphoma, and EC.\(^23\)\(^-\)\(^27\) Although the expression level of syncytin-1 varies in different tumors, the pathological significance of its non-fusion activity remains to be studied. However, current evidence suggests that measuring syncytin-1 expression levels in cancer tissues may have some prognostic values for certain tumor types and stages.\(^28\)

In this study, we verified the roles of syncytin-1 in EC cell proliferation, migration, and invasion and identified the mechanisms of syncytin-1 in EC, such as its relationship with epithelial-mesenchymal transition (EMT)-related pathway genes. We found that syncytin-1 may be a novel therapeutic target for the treatment of EC.

**Materials and methods**

**Immunohistochemistry**

A total of 130 archived clinical EC specimens and 12 normal endometrial tissues were obtained at the Binzhou Medical University Hospital of China between January 2012 and January 2015 with patient anonymity and informed consent. This study was approved by the Ethical Review Committee of Binzhou Medical University Hospital. All cell lines were cultured in RPMI-1640 medium (Hyclone, Logan, UT, USA) supplemented with 10% FBS (Thermo Fisher Scientific, Waltham, MA, USA). The cells were cultured at 37°C in a humidified atmosphere containing 5% CO\(_2\). Transfection was performed using Lipofectamine 2000 Reagent (Thermo Fisher Scientific) following the manufacturer’s instructions.

**Quantitative real-time PCR (qRT-PCR) analysis**

Total RNA was extracted from the tissues using Trizol reagent (TaKaRa, Shiga, Japan) following the manufacturer’s instructions. cDNA was synthesized from 1 μg of total RNA using the transcriptor first strand cDNA synthesis kit (Hoffman-La Roche Ltd., Basel, Switzerland). Real-time PCR was performed by Faststart Universal SYBR Green Master (Hoffman-La Roche Ltd.). The primers were synthesized by Sangon Biotech Co., Ltd. (Shanghai, China). The primers were as follows (5’-3’): syncytin-1 forward primer: GGAGGAGATGTGGCACCATT, reverse primer: CCTTCCACCACAGAAGACC. \(\beta\)-actin forward primer: TGCTGTCCCTGTATGCCTCT, and reverse primer: AAGTCTTTACGGATGTCAACG. Data were analyzed by the method of \(2^{-\Delta\Delta Ct}\).

**Western blotting**

For Western blot analysis, approximately 10 μg of proteins were loaded and separated on the BioRad mini gel system (Bio-Rad Laboratories Inc., Hercules, CA, USA). Protein expression of syncytin-1 and GAPDH was detected by incubating with antibodies anti-syncytin-1 and anti-GAPDH (ZSGB-BIO, Beijing, China) at a dilution of 1:1,000.
overnight at 4°C in primary antibodies. The membranes were then incubated for 2 h at room temperature in HRP-labeled secondary antibody (Pierce, Rockford, IL, USA) (1:1,000). The bands were visualized using colorimetric detection and exposure to autoradiography film.

**Cell cycle analysis**

RL-95-2 cell was seeded in a six-well plate, incubated for 24 hours, and then collected for cell cycle analysis as previously described.

**Plasmid construction and transfection**

The complete sequence of human syncytin-1 gene was synthesized and inserted into a pcDNA3.1 (+) vector (GenePharma, Shanghai, China) to construct the pcDNA3.1-Syncytin-1 expression vector. RL-95-2 cells (5×10⁴ cells) at the logarithmic phase were inoculated in six-well plates and incubated for 12 hours. The cells were then transfected with pcDNA3.1 and pcDNA3.1-syncytin-1 plasmid by using Lipofectamine 2000 reagent (cat. no 11668-019; Thermo Fisher Scientific) and Opti-MEM-reduced serum medium (Thermo Fisher Scientific) according to the manufacturer’s instructions until the cell fusion rate reached 80%.

**Cell counting kit (CCK)-8 assay**

HECCL-1 and RL-95-2 cells seeded in 96-well plates (2,000 cells/well) were allowed to attach overnight and then left untreated or treated with Au–NPs (5, 10, 20, 40, 50, or 60 nm) for 24 hours. Assay reagent (cat. no KGA317; CCK-8; Kaiji, Nanjing, China) was subsequently added to each well, followed by an incubation for 1, 2, 3, and 4 hours. Absorbance values at 450 nm were recorded using a microplate reader (iMark Microplate Absorbance Reader; Bio-Rad Laboratories, Inc.). The results from each of the four time points were averaged, and cell viability was calculated as a percentage of the untreated control. Each experiment was performed in triplicate, and the experiment was repeated three times.

**Transwell assay**

Cell migration and invasion were confirmed by detecting the ability of cells to move to another place. The cells at the logarithmic phase were digested, washed with PBS twice, and suspended in RPMI-1640 medium without FBS. The concentration was adjusted to 2×10⁵ cells/mL. Cell suspensions (100 μL) were added to the polycarbonate membrane of the upper chamber with (for the invasion assay) or without (for the migration assay) Matrigel (BD Biosciences, San Jose, CA, USA). The bottom chamber was filled with complete medium (500 μL). The cells were incubated at 37°C for 24 hours. The cells on the bottom of the coated Transwell chamber were washed twice, fixed with 4% paraformaldehyde (CatP6148) for 30 minutes, and stained with 0.1% crystal violet (no C3886-100G0; Sigma-Aldrich Co., St Louis, MO, USA) for 15 minutes at room temperature. After drying, the number of migrated or invaded cells was examined from five randomly selected fields under a microscope at a magnification of ×100.

**Statistical analyses**

Statistical analyses of experimental data were conducted with Prism 5.0 (GraphPad Software, Inc., La Jolla, CA, USA). All results are presented as the mean ± SD from at least three independent experiments. *P*<0.05 was considered statistically significant.

**Ethics statement**

This study was approved by the Ethics Committee of the Binzhou Medical College Affiliated Hospital (No 2018-024-03).

**Results**

**Validation of syncytin-1 expression in EC and noncancerous tissues**

To validate the profile and characterize the expression pattern of syncytin-1 in EC, we collected three pairs of fresh EC and adjacent normal tissues. RT-PCR showed that syncytin-1 mRNA level was significantly increased in EC compared with the adjacent normal tissues in samples 1 and 2 (*P*<0.001) but not in sample 3 (*P*>0.05) (Figure 1A). We believe that the possible reason is the genetic heterogeneity for the different samples.

**Correlation analysis of syncytin-1 expression and clinicopathological parameters of EC**

A total of 130 archived clinical EC specimens and 37 normal endometrial tissues were examined by immunohistochemistry analysis to assess the relationship between the expression of syncytin-1 and the progression of EC (Table 1). The results showed that syncytin-1 was mainly localized in the cytoplasm (Figure 1B). Syncytin-1 was highly expressed in 15 out of 37 (40.54%) cases of human normal endometrial tissues and in 83 out of 130 (63.85%) cases of EC with significant difference (*χ²=6.452, *P*=0.011). Statistical analyses were performed to explore the correlation
between syncytin-1 expression and the clinical characteristics of EC as detected by immunohistochemical staining. The result of chi-square test showed that syncytin-1 expression was positively correlated with tumor FIGO stages ($P=0.001$), expression of ER ($P=0.018$), and expression of Ki-67 ($P=0.037$) (Table 2), thereby indicating that these clinical features are correlated with syncytin-1 expression.

Syncytin-1 expression was related to the overall survival of EC

Kaplan–Meier analysis was used to assess the overall survival according to syncytin-1 expression and to further explore the correlation between syncytin-1 expression and EC survival. The results showed that the mean survival time was 39.18±4.36 months in patients with EC and high syncytin-1 expression and 51.12±2.78 months in those with low expression of syncytin-1. The 5-year cumulative survival rate was 32.8% in patients with EC and high syncytin-1 expression and 60.7% in those with low expression of syncytin-1. Patients with EC and high expression of syncytin-1 have a poor prognosis (Figure 1C, \( \chi^2 = 14.512, P < 0.001 \)). Therefore, syncytin-1 expression is associated with survival and prognosis.

Expression of syncytin-1 in EC cell lines

We evaluated the expression of syncytin-1 in EC cell lines KLE, RL-95-2, HECCCL-1, HEC-1-A, and JEC and immortalized endometrial epithelial EM-E6/E7-TERT. Western blot analysis showed that the expression of syncytin-1 protein was markedly increased in KLE and RL-95-2 but was low in other EC cell lines. We believe that this phenomenon is the result of the selective expression of genes that control traits in time and space. The expression of syncytin-1 in all EC cell lines was significantly higher than that in normal endometrial
Table 1: Clinicopathological characteristics of patient samples

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Number of cases (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td></td>
</tr>
<tr>
<td>≤50</td>
<td>51 (39.2)</td>
</tr>
<tr>
<td>&gt;50</td>
<td>79 (60.8)</td>
</tr>
<tr>
<td>FIGO stage</td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>71 (54.6)</td>
</tr>
<tr>
<td>II</td>
<td>38 (29.2)</td>
</tr>
<tr>
<td>III</td>
<td>21 (16.2)</td>
</tr>
<tr>
<td>IV</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Pathological differentiation</td>
<td></td>
</tr>
<tr>
<td>Well</td>
<td>109 (83.8)</td>
</tr>
<tr>
<td>Poor</td>
<td>21 (16.2)</td>
</tr>
<tr>
<td>Expression of syncytin-1</td>
<td></td>
</tr>
<tr>
<td>High</td>
<td>83 (63.8)</td>
</tr>
<tr>
<td>Low</td>
<td>47 (36.2)</td>
</tr>
<tr>
<td>Expression of ER</td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>18 (13.8)</td>
</tr>
<tr>
<td>Positive</td>
<td>112 (86.2)</td>
</tr>
<tr>
<td>Expression of PR</td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>13 (10.0)</td>
</tr>
<tr>
<td>Positive</td>
<td>117 (90.0)</td>
</tr>
<tr>
<td>Expression of Ki-67</td>
<td></td>
</tr>
<tr>
<td>≤20%</td>
<td>17 (13.1)</td>
</tr>
<tr>
<td>&gt;20%</td>
<td>113 (86.9)</td>
</tr>
</tbody>
</table>

Table 2: Clinicopathological characteristics of patient samples and expression of syncytin-1 in EC and correlation between syncytin-1 expression and clinicopathological characteristics of EC patients

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Total</th>
<th>Syncytin-1</th>
<th>Chi-squared test</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td></td>
<td>High</td>
<td>Low</td>
<td></td>
</tr>
<tr>
<td>≤50</td>
<td>51</td>
<td>33</td>
<td>18</td>
<td>0.027</td>
</tr>
<tr>
<td>&gt;50</td>
<td>79</td>
<td>50</td>
<td>29</td>
<td>0.870</td>
</tr>
<tr>
<td>FIGO stage</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>71</td>
<td>35</td>
<td>36</td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>38</td>
<td>31</td>
<td>7</td>
<td>14.351</td>
</tr>
<tr>
<td>III</td>
<td>21</td>
<td>17</td>
<td>4</td>
<td>0.001</td>
</tr>
<tr>
<td>IV</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Pathological differentiation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Well</td>
<td>109</td>
<td>69</td>
<td>40</td>
<td>0.086</td>
</tr>
<tr>
<td>Poor</td>
<td>21</td>
<td>14</td>
<td>7</td>
<td>0.769</td>
</tr>
<tr>
<td>Expression of ER</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>18</td>
<td>7</td>
<td>11</td>
<td>5.638</td>
</tr>
<tr>
<td>Positive</td>
<td>112</td>
<td>76</td>
<td>36</td>
<td>0.018</td>
</tr>
<tr>
<td>Expression of PR</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>13</td>
<td>10</td>
<td>3</td>
<td>1.070</td>
</tr>
<tr>
<td>Positive</td>
<td>117</td>
<td>73</td>
<td>44</td>
<td>0.301</td>
</tr>
<tr>
<td>Expression of Ki-67</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤20%</td>
<td>17</td>
<td>7</td>
<td>10</td>
<td>4.354</td>
</tr>
<tr>
<td>&gt;20%</td>
<td>113</td>
<td>76</td>
<td>37</td>
<td>0.037</td>
</tr>
<tr>
<td>Tissue</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EC</td>
<td>130</td>
<td>83</td>
<td>47</td>
<td>6.452</td>
</tr>
<tr>
<td>Normal</td>
<td>37</td>
<td>15</td>
<td>22</td>
<td>0.011</td>
</tr>
</tbody>
</table>

Abbreviation: EC, endometrial carcinoma.

potential mechanism of syncytin-1

Syncytin-1 promotes EC cell proliferation

Establishment of a stable syncytin-1-overexpressing cell line

Syncytin-1 promotes EC cell migration and invasion

Syncytin-1 promotes G2/M phase transition in the cell cycle of EC
Figure 2 Expression of syncytin-1 in EC cell lines by Western blot.
Notes: (A and B) Syncytin-1 is highly expressed in KLE and RL-95-2 cell lines. Its expression in all EC cell lines was higher than that in normal endometrial epithelial cell line EM-E6/E7-TERT. *P<0.05. (C) Overexpression of syncytin-1 in HECCL-1 cell line, detection of tag flag. (D) shSyncytin-1 expression in RL-95-2 cell lines.
Abbreviation: EC, endometrial carcinoma.

Figure 3 CCK-8 and plate cloning experiment detect the growth ability of cell line.
Notes: (A–C) Comparison with the control group using a CCK-8 assay and late cloning experiment showed that overexpression of syncytin-1 significantly promotes HECCL-1 tumor cell growth. *P<0.01. (D–F) Comparison with the shNC group using a CCK-8 assay and plate cloning experiment confirmed that shSyncytin-1 significantly suppresses the proliferation in RL-95-2 tumor cell growth. *P<0.01.
can significantly increase the proportion of G2/M (from 11.29% to 37.62%) and the percentage of S-phase cells (from 16.68% to 42.56%) (Figure 5). This finding showed that inhibiting the expression of syncytin-1 promotes cell stagnation in the RL-95-2 cell lines. Syncytin-1 stimulates the change in G2-M phase, thereby inducing many paralyzed cells to enter mitosis.

**Effects of syncytin-1 on the expression of EMT-related proteins**

To explore the mechanism underlying the cell cycle arrest, we detected the expression levels of the cell cycle-related proteins by Western blot analysis. The results showed that overexpression of syncytin-1 can significantly regulate the changes in EMT-related molecules mainly by promoting the expression of vimentin, E-cadherin, slug, and ZEB1 and by inhibiting the expression of N-cadherin and snail in HECCL-1 cells. shSyncytin-1 could decrease the expression of vimentin, E-cadherin, slug, and ZEB1 in RL-95-2 cells (Figure 6).

**Effects of syncytin-1 on the expression of AKT-related proteins**

The association between syncytin-1 and AKT was investigated through Western blot to clarify the role of the former in the progression of human EC and to elucidate the underlying mechanism. Overexpression of syncytin-1 and shSyncytin-1 was not correlated with the AKT-related genes (total-AKT, p-AKT, and vinculin) in HECCL-1 and RL-95-2 cells (Figure 7).

**Discussion**

Syncytin-1 is a common protein in human reproductive system envelope and is located in the first trimester
trophoblast. Its abnormal expression may lead to intrauterine growth retardation, pathological embryonic, tumor, and multiple sclerosis. This protein has critical roles in many diseases. However, the exact regulatory mechanism of syncytin-1 in EC is poorly understood. To solve this problem, we transfected the expression of syncytin-1 in EC cells by pc-Syncytin-1 and shSyncytin-1 and analyzed the effect of the abnormal expression of syncytin-1 on cell proliferation and cell metastasis.

According to our clinical and biochemical data, syncytin-1 is upregulated in EC tissues and cell lines. Further studies found that syncytin-1 can promote cell proliferation, migration, and invasion and the change in G2-M phase. These findings suggest that syncytin-1 may be a regulatory gene for EC. EMT is an effective way for epithelial cells to acquire migratory capacity and has become an important pathway for invasion and metastasis of epithelial cell carcinoma. Various studies showed that the development of EMT is accompanied with changes in markers, including E-cadherin, N-cadherin, and vimentin. In the present study, syncytin-1 significantly promotes the expression of vimentin, E-cadherin, slug, and ZEB1 protein but inhibits the expression of N-cadherin and snail. This finding indicates a new molecular mechanism by which syncytin-1 regulates cell migration in EC cells.

Figure 5 Apoptosis and proliferation changes by shSyncytin-1 in RL-95-2 cells.

Figure 6 Effects of syncytin-1 on the expression of specific proteins.
Notes: (A) Western blot analysis showed that overexpression of syncytin-1 could increase the expression of vimentin, E-cadherin, slug, and ZEB1 protein. (B) shSyncytin-1 could decrease the expression of vimentin, E-cadherin, slug, and ZEB1 protein.

Figure 7 Effects of syncytin-1 on the expression of AKT-related proteins.
Notes: (A) Western blot analysis showed that overexpression of syncytin-1 could not increase the expression of total-AKT, p-AKT, and vinculin protein. (B) AKT-related proteins were detected by Western blotting after shSyncytin-1 treatment.
Conclusion
Syncytin-1 plays as a tumor promoter in the occurrence and carcinogenesis of EC. Understanding the precise function of syncytin-1 in complex networks may provide further insights into the progression of EC and offers a promising therapeutic target for the treatment of this disease.

Acknowledgment
This research was supported by grants from the Medicine and Health and Scientific Development Programme of Shandong Province (2015WSB30011) and the Scientific Development Programme of Binzhou Medical University (BY2014KJ45, BY2017KJ09).

Disclosure
The authors report no conflict of interest in this work.

References